Skip to content

The oscillation for acute respiratory distress syndrome (ARDS) treated early trial

High frequency oscillation versus best current conventional ventilation to reduce acute respiratory distress syndrome (ARDS) mortality: a multicentre randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN87124254
Enrollment
1200
Registered
2009-05-11
Start date
2009-06-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome (ARDS) Respiratory Adult respiratory distress syndrome

Interventions

Intervention group: high frequency oscillatory (HFO) ventilation using a lung-open approach and an explicit protocol. Control group: conventional ventilation using low tidal volumes, a lung-open appro

Sponsors

Canadian Critical Care Trials Group (Canada)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Acute onset of respiratory failure, with fewer than 2 weeks of new pulmonary symptoms 2. Endotracheal intubation or tracheostomy 3. Hypoxaemia - defined as a partial pressure of oxygen in arterial blood (PaO2)/fraction of inspired oxygen (FiO2) less than or equal to 200 mmHg on FiO2 greater than or equal to 0.5, regardless of positive end expiratory pressure (PEEP) 4. Bilateral alveolar consolidation (airspace disease) seen on frontal chest radiograph 5. Aged 16 years or over, either sex. No upper age limit. In addition, to qualify for randomisation, patients are assessed on the following ventilator settings: 6. Mode: pressure control or volume control or pressure support 7. FiO2 greater than 0.6 (or higher if necessary to keep pulse oximetric saturation [SpO2] greater than 90%) 8. PEEP greater than 10 cm H2O (or greater if necessary to keep SpO2 greater than 90%) 9. Tidal volume 6 ml/kg predicted body weight (PBW) After at least 30 minutes on these settings, we sample arterial blood to assess oxygenation. If PaO2 is less than or equal to 200 mmHg, the patient qualifies for randomisation; if PaO2/FiO2 greater than 200 mmHg, standardised hypoxaemia assessments are repeated at least once daily for the following 72 hours (providing the eligibility criteria are still met).

Exclusion criteria

Exclusion criteria: 1. Remaining duration of mechanical ventilation less than 48 hours, as judged by the attending physician 2. Primary cause of acute respiratory failure judged by attending physician to be circulatory overload due to, for example, congestive heart failure, hyper-resuscitation, or need for dialysis 3. Suspected pulmonary haemorrhage syndrome 4. Lack of commitment to ongoing life support (note that this does not include the presence of a "Do Not Resuscitate" order alone, if there is a commitment to ongoing life support) 5. Aged less than 16 years 6. Weight less than 35 kg 7. Severe chronic respiratory disease, as indicated by any of: 7.1. Baseline forced expriatory volume in one second (FEV1) less than 20 ml/kg predicted body weight 7.2. Pre-existing chronic interstitial lung disease with chronic interstitial infiltration on chest X-ray 7.3. Documented chronic carbon dioxide (CO2) retention (partial pressure of carbon dioxide in arterial blood [PaCO2] less than 50 mmHg) and/or chronic hypoxaemia (PaO2 less than 55 mmHg on FiO2 = 0.21) 7.4. Chronic restrictive, obstructive, neuromuscular, chest wall or pulmonary vascular disease resulting in severe exercise restriction (e.g., unable to climb stairs or perform household duties), secondary polycythaemia, severe pulmonary hypertension (mean pulmonary artery pressure [PAP] greater than 40 mmHg), or ventilator dependency 8. Morbid obesity - defined as greater than 1 kg/cm body height 9. Underlying pre-existing condition with expected 6-month mortality greater than 50% 10. Neurological conditions with risk of intracranial hypertension (where hypercapnia should be avoided) 11. Neuromuscular disease that will result in prolonged need for mechanical ventilation, including (but not limited to): 11.1. Guillain Barré syndrome 11.2. Cervical spinal cord injury 12. Previous randomisation in this trial 13. All inclusion criteria present for greater than 72 hours in study intensive care unit (ICU) 14. On HFO at the time of screening

Design outcomes

Primary

MeasureTime frame
All-cause in-hospital mortality

Secondary

MeasureTime frame
1. Mortality at other time-points (ICU discharge, 28-day) 2. Barotrauma 3. Organ dysfunction 4. Duration of mechanical ventilation 5. Duration of ICU and hospital stay 6. Quality of life at 6 months

Countries

Canada, Chile, France, Germany, India, Saudi Arabia, Singapore, Spain, United Kingdom, United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 24, 2026